Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04348747
Title Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Roswell Park Cancer Institute

Her2-receptor positive breast cancer

triple-receptor negative breast cancer


Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod

Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Rintatolimod

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Roswell Park Cancer Institute Recruiting Buffalo New York 14263 United States Details
*Shaded cells indicate that there was no data available from for the field